Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-01-04 Sale |
2023-01-06 5:19 pm |
Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel |
1,138 | $37.21 | $42,345 | 19,559 (Direct) |
View |
| 2022-01-01 Sale |
2022-03-04 9:07 pm |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
2,493 | $112.25 | $279,852 | 907,552 (Indirect Direct) |
View |
| 2022-01-01 Sale |
2022-03-03 8:03 pm |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
1,148 | $112.25 | $128,863 | 42,947 (Direct) |
View |
| 2022-01-01 Sale |
2022-03-03 8:00 pm |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
1,051 | $112.24 | $117,964 | 48,117 (Direct) |
View |
| 2022-01-01 Sale |
2022-03-03 7:38 pm |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
1,013 | $112.24 | $113,699 | 36,677 (Direct) |
View |
| 2021-11-05 Sale |
2021-11-09 6:08 pm |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $132.72 | $318,535 | 188,791 (Direct) |
View |
| 2021-10-14 Sale |
2021-10-15 7:02 pm |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $128.44 | $308,249 | 191,191 (Direct) |
View |
| 2021-10-11 Sale |
2021-10-13 4:15 pm |
Intellia Therapeutics Inc. | NTLA | Crowley John F Director |
2,500 | $119.55 | $298,875 | 27,594 (Direct) |
View |
| 2021-10-05 Sale |
2021-10-07 5:41 pm |
Intellia Therapeutics Inc. | NTLA | Crowley John F Director |
10,000 | $130.54 | $1,305,391 | 30,094 (Direct) |
View |
| 2021-09-21 Sale |
2021-09-23 5:48 pm |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $149.81 | $359,544 | 193,591 (Direct) |
View |
| 2021-09-07 Sale |
2021-09-09 5:38 pm |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
3,482 | $180.12 | $627,178 | 12,451 (Direct) |
View |
| 2021-08-30 Sale |
2021-09-01 8:21 pm |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
121,372 | $160.83 | $19,520,418 | 1,219,569 (Indirect Direct) |
View |
| 2021-08-30 Sale |
2021-09-01 7:34 pm |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
97,000 | $154.83 | $15,018,054 | 164,391 (Direct) |
View |
| 2021-08-30 Sale |
2021-09-01 7:32 pm |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $158.04 | $379,300 | 195,991 (Direct) |
View |
| 2021-08-30 Sale |
2021-09-01 7:30 pm |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
30,000 | $159.45 | $4,783,538 | 122,550 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-01-01 Exercise |
2023-01-04 8:38 pm |
2023-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
3,500 | $0 | 29,467 (Direct) |
View |
| 2023-01-01 Exercise |
2023-01-04 8:36 pm |
2023-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
7,848 | $0 | 847,611 (Direct) |
View |
| 2023-01-01 Exercise |
2023-01-04 8:33 pm |
2023-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
3,187 | $0 | 34,637 (Direct) |
View |
| 2023-01-01 Exercise |
2023-01-04 8:29 pm |
2023-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
3,062 | $0 | 23,957 (Direct) |
View |
| 2022-06-14 Option Award |
2022-06-16 6:46 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | Verwiel Frank Director |
12,885 | $0 | 14,979 (Direct) |
View |
| 2022-06-14 Option Award |
2022-06-16 6:40 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | Keresty Georgia Director |
12,885 | $0 | 19,409 (Direct) |
View |
| 2022-06-14 Option Award |
2022-06-16 6:36 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | GOODMAN JESSE Director |
12,885 | $0 | 14,979 (Direct) |
View |
| 2022-06-14 Option Award |
2022-06-16 6:33 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | FORMELA JEAN FRANCOIS Director |
12,885 | $0 | 14,979 (Direct) |
View |
| 2022-06-14 Option Award |
2022-06-16 6:26 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | DORSA CAROLINE Director |
12,885 | $0 | 20,389 (Direct) |
View |
| 2022-06-14 Option Award |
2022-06-16 6:24 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | Crowley John F Director |
12,885 | $0 | 14,979 (Direct) |
View |
| 2022-06-14 Option Award |
2022-06-16 6:22 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | Cohen Fred E Director |
12,885 | $0 | 44,979 (Direct) |
View |
| 2022-06-14 Option Award |
2022-06-16 6:19 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | Bhanji Muna Director |
4,994 | $0 | 12,948 (Direct) |
View |
| 2022-04-28 Option Award |
2022-05-02 9:49 pm |
N/A 2032-04-27 |
Intellia Therapeutics Inc. | NTLA | Bhanji Muna Director |
19,654 | $0 | 19,654 (Direct) |
View |
| 2021-06-23 Option Award(A) |
2022-04-14 8:44 pm |
N/A 2031-06-22 |
Intellia Therapeutics Inc. | NTLA | Keresty Georgia Director |
4,103 | $0 | 9,058 (Direct) |
View |
| 2022-03-01 Option Award |
2022-03-07 7:19 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer |
25,922 | $0 | 31,560 (Direct) |
View |
Ownership |
2022-03-07 7:15 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer |
0 | $0 | 99,888 (Direct) |
View |
| 2022-03-01 Option Award(A) |
2022-03-04 9:09 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel |
14,109 | $0 | 14,109 (Direct) |
View |
| 2022-01-01 Exercise |
2022-03-04 9:07 pm |
2022-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
7,848 | $0 | 907,552 (Direct) |
View |
| 2022-03-01 Option Award |
2022-03-04 9:07 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
100,931 | $0 | 907,552 (Direct) |
View |
| 2022-03-01 Option Award(A) |
2022-03-04 9:04 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
18,600 | $0 | 18,600 (Direct) |
View |
| 2022-03-01 Option Award(A) |
2022-03-04 9:01 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
20,203 | $0 | 20,203 (Direct) |
View |
| 2022-03-01 Option Award(A) |
2022-03-04 8:58 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
20,203 | $0 | 20,203 (Direct) |
View |
| 2022-01-01 Exercise |
2022-03-03 8:03 pm |
2022-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
3,500 | $0 | 42,947 (Direct) |
View |
| 2022-03-01 Option Award |
2022-03-03 8:03 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
13,816 | $0 | 42,947 (Direct) |
View |
| 2022-01-01 Exercise |
2022-03-03 8:00 pm |
2022-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
3,187 | $0 | 48,117 (Direct) |
View |
| 2022-03-01 Option Award |
2022-03-03 8:00 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
13,816 | $0 | 48,117 (Direct) |
View |
| 2022-01-01 Exercise |
2022-03-03 7:38 pm |
2022-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
3,062 | $0 | 36,677 (Direct) |
View |
| 2022-03-01 Option Award |
2022-03-03 7:38 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
12,720 | $0 | 36,677 (Direct) |
View |
| 2022-03-01 Option Award |
2022-03-03 7:34 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel |
20,697 | $0 | 30,345 (Direct) |
View |
| 2022-01-03 Option Award |
2022-01-05 4:15 pm |
N/A 2032-01-02 |
Intellia Therapeutics Inc. | NTLA | Hicks Derek EVP, Chief Business Officer |
44,118 | $0 | 44,118 (Direct) |
View |
| 2021-11-05 Exercise |
2021-11-09 6:08 pm |
N/A 2030-04-30 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $0 | 188,791 (Direct) |
View |
| 2021-11-05 Exercise |
2021-11-09 6:08 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $12.62 | 188,791 (Direct) |
View |
| 2021-10-14 Exercise |
2021-10-15 7:02 pm |
N/A 2030-04-30 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $0 | 191,191 (Direct) |
View |
| 2021-10-14 Exercise |
2021-10-15 7:02 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $12.62 | 191,191 (Direct) |
View |
| 2021-10-11 Exercise |
2021-10-13 4:15 pm |
N/A 2030-10-01 |
Intellia Therapeutics Inc. | NTLA | Crowley John F Director |
2,500 | $0 | 27,594 (Direct) |
View |
| 2021-10-11 Exercise |
2021-10-13 4:15 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Crowley John F Director |
2,500 | $18.83 | 27,594 (Direct) |
View |
| 2021-10-05 Exercise |
2021-10-07 5:41 pm |
N/A 2030-10-01 |
Intellia Therapeutics Inc. | NTLA | Crowley John F Director |
10,000 | $0 | 30,094 (Direct) |
View |
| 2021-10-05 Exercise |
2021-10-07 5:41 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Crowley John F Director |
10,000 | $18.83 | 30,094 (Direct) |
View |
| 2021-09-24 Exercise |
2021-09-27 4:15 pm |
N/A 2030-04-30 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
7,923 | $0 | 193,591 (Direct) |
View |
| 2021-09-24 Exercise |
2021-09-27 4:15 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
7,923 | $12.62 | 193,591 (Direct) |
View |
| 2021-09-21 Exercise |
2021-09-23 5:48 pm |
N/A 2030-04-30 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $0 | 193,591 (Direct) |
View |
| 2021-09-21 Exercise |
2021-09-23 5:48 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $12.62 | 193,591 (Direct) |
View |
| 2021-09-07 Exercise |
2021-09-09 5:38 pm |
N/A 2028-12-17 |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
3,482 | $0 | 12,451 (Direct) |
View |
| 2021-09-07 Exercise |
2021-09-09 5:38 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
3,482 | $14.58 | 12,451 (Direct) |
View |
| 2021-09-01 Exercise |
2021-09-01 8:21 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
28,750 | $23.46 | 1,219,569 (Direct) |
View |
| 2021-08-30 Exercise |
2021-09-01 8:21 pm |
N/A 2030-03-01 |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
121,372 | $0 | 1,219,569 (Direct) |
View |
| 2021-08-30 Exercise |
2021-09-01 8:21 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
11,637 | $13.4 | 1,219,569 (Direct) |
View |
| 2021-08-30 Exercise |
2021-09-01 8:21 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
65,000 | $14.58 | 1,219,569 (Direct) |
View |
| 2021-09-01 Exercise |
2021-09-01 8:21 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
15,985 | $18.3 | 1,219,569 (Direct) |
View |
| 2021-08-30 Exercise |
2021-09-01 7:34 pm |
N/A 2030-03-01 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
97,000 | $0 | 164,391 (Direct) |
View |
| 2021-08-30 Exercise |
2021-09-01 7:34 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
70,000 | $14.25 | 164,391 (Direct) |
View |
| 2021-08-30 Exercise |
2021-09-01 7:34 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
27,000 | $13.4 | 164,391 (Direct) |
View |
| 2021-08-30 Exercise |
2021-09-01 7:32 pm |
N/A 2030-05-04 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $0 | 195,991 (Direct) |
View |
| 2021-08-30 Exercise |
2021-09-01 7:32 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $12.62 | 195,991 (Direct) |
View |
| 2021-08-30 Exercise |
2021-09-01 7:30 pm |
N/A 2028-10-31 |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
30,000 | $0 | 122,550 (Direct) |
View |
| 2021-08-30 Exercise |
2021-09-01 7:30 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
28,183 | $19.27 | 122,550 (Direct) |
View |
| 2021-08-31 Exercise |
2021-09-01 7:30 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
1,817 | $14.58 | 122,550 (Direct) |
View |